Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pradaxa Bleeding Events Prompt FDA To Revise Generic Bioequivalence Criteria

This article was originally published in The Pink Sheet Daily

Executive Summary

Revamped ANDA instructions – among new and revised draft guidance for 58 products announced by FDA – 'account for the fact that dabigatran exhibits large within-subject variability with respect to blood levels.'


Related Content

Boehringer Avoids Pradaxa Trial, Board Chair Deposition With $650 Mil. Settlement
Mini Sentinel Alleviates FDA Concern Over Pradaxa Bleeding Issue
Pradaxa Bleeding Deaths Spur FDA Concerns, European Label Changes


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts